好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exploring Radiculopathy in Underserved Communities: A Focus on AANHPI Populations and Risk Factors
Health Care Disparities
P5 - Poster Session 5 (5:30 PM-6:30 PM)
4-005
NA
Radiculopathy (RP) is a debilitating nerve compression condition. This study aims to address the paucity of research on RP in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) populations and to identify differences in clinical presentation, comorbidities, and treatment of AANHPI compared to other ethnocultural groups in Hawaii.

This retrospective cohort study utilizes data from a single neurological center in Hawaii. Adults aged ≥18 years diagnosed with RP between 2016-2023 were identified using ICD10 codes. Patients without electromyography, magnetic renaissance imaging, or insufficient demographical data were excluded. Statistical analysis was completed on R, with p<0.05 considered statistically significant.
Data from 1287 out of 1,764 patients are included in the analysis, with 477 excluded. The cohort consisted of 28% Asians and 20% NHPIs. NHPIs had the youngest age of diagnosis, while Asians had the highest age of diagnosis (p<0.001). AANHPI populations were more likely to have public insurance (p<0.001). NHPIs had the highest rates of obesity (p<0.001), while Asians had the lowest (p<0.001). AANHPIs were more likely to have more than two medical comorbidities (p<0.001) and higher rates of hypertension (p<0.001), hyperlipidemia (p<0.001), hypercholesterolemia (p<0.001), and diabetes (p<0.001). AANHPIs were mainly treated with medications and were less likely to have received physical therapy, steroid injections, or surgery  (p=0.042)
AANHPI patients are more likely to be publicly insured,  have multiple comorbidities, and are less likely to receive specialized treatments. NHPI  are diagnosed earlier and have higher rates of obesity. These findings are important for addressing underlying comorbidities and treatment disparities amongst AANHPI patients.
Authors/Disclosures
Anita Cheung, MPH
PRESENTER 		Miss Cheung has nothing to disclose.
Matthew Nishimura (Hawaii Pacific Neuroscience) No disclosure on file
Tea Stephens No disclosure on file
Kai Miyaki No disclosure on file
Edward Weldon (John A. Burns School of Medicine) Edward Weldon has nothing to disclose.
Julia Jahansooz Julia Jahansooz has nothing to disclose.
Anson Lee (University of Hawaii John A. Burns School of Medicine) Anson Lee has nothing to disclose.
Masako Matsunaga (University of Hawaii at Manoa) Masako Matsunaga has nothing to disclose.
Jason Chang (Hawaii Pacific Neuroscience) No disclosure on file
Enrique Carrazana (Neurelis, Inc.) Enrique Carrazana has received personal compensation for serving as an employee of Neurelis. Enrique Carrazana has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Hawaii-Biotech, CND Life Sciences, Apex Labs. Enrique Carrazana has stock in Neurelis, CND, Apex.
Jason Viereck, MD, PhD (Adventist Health Castle Hospital) Dr. Viereck has nothing to disclose.
Kore K. Liow, MD, FACP (University of Hawaii, John Burns School of Medicine) The institution of Dr. Liow has received research support from UCB. The institution of Dr. Liow has received research support from Livanova. The institution of Dr. Liow has received research support from Biogen. The institution of Dr. Liow has received research support from Novartis. The institution of Dr. Liow has received research support from Eisai. The institution of Dr. Liow has received research support from Engage Therapeutics. The institution of Dr. Liow has received research support from SK Lifescience. The institution of Dr. Liow has received research support from Cerevel. The institution of Dr. Liow has received research support from Xenon. The institution of Dr. Liow has received research support from NeuroDerm. The institution of Dr. Liow has received research support from Avanir. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Acadia. The institution of Dr. Liow has received research support from Prothena. The institution of Dr. Liow has received research support from SAGE. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Cyclerion.